The Federal Trade Commission (FTC) has initiated an investigation into Teva Pharmaceutical Industries Ltd (NYSE:TEVA) over its refusal to remove about two dozen patents for its asthma and COPD inhalers. This move comes amid accusations that Teva has engaged in practices to maintain market exclusivity and block generic competition. Related: Federal Trade Commission Targets’ Junk Patent Listings’ For Diabetes, Weight Loss, Asthma Drugs From Companies Like Novo Nordisk, AstraZeneca. Confidential agency documents reviewed by The Washington Post revealed that the FTC last week issued a civil investigative demand, effectively a subpoena, to ...